Allarity Receives Key U.S. Patent for Stenoparib DRP Companion Diagnostic
Allarity Therapeutics announced the USPTO has granted a key patent covering its stenoparib DRP companion diagnostic. This milestone secures exclusivity for stenoparib until 2042, validating the company's strategy for precision oncology and supporting FDA approval efforts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day